Inhalable bionic nanoparticle vaccine mimicking pulmonary surfactant enhances anti-tuberculosis immunity
European Cells & Materials · 29.05.2026 · 57
DOI: 10.22203/ecm.v057a03 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Cells & Materials, online erschienen am 29.05.2026. Verfasst von Yanqiu Wu und 15 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis (M.tb), remains a formidable global public health threat. The currently available Bacillus Calmette-Guérin (BCG) vaccine, while effective in children, provides inadequate protection for adults, highlighting an urgent need for novel vaccine development.
Methods
This study constructed an inhalable biomimetic nanoparticle vaccine, designated ECQ@PS-LPs. The vaccine utilizes liposomes that mimic natural pulmonary surfactant as a carrier to co-encapsulate two key TB antigens, ESAT-6 and CFP-10, along with the immunoadjuvant QS-21. Following intranasal administration in mice, immune responses and protective efficacy were evaluated. Using one-way ANOVA with post-hoc testing, statistical significance was defined as *p < 0.05, **p < 0.01 and ***p < 0.001.
Results
The ECQ@PS-LPs vaccine effectively breached the alveolar surfactant barrier, significantly enhancing uptake by antigen-presenting cells. This triggered a robust multidimensional immune response, including potent cellular immunity (characterized by Th1 and Th17 responses), systemic humoral immunity (indicated by IgG production), and strong mucosal immunity (evidenced by sIgA). Furthermore, the vaccine induced durable immune memory, marked by the generation of tissue-resident memory T cells (TRM) and central memory T cells (TCM). In a M.tb challenge model, ECQ@PS-LPs conferred a level of protection comparable to the BCG vaccine and elicited a superior mucosal immune response. The vaccine formulation also demonstrated a simple preparation process and favorable biological safety profile.
Conclusions
ECQ@PS-LPs represents a promising inhalable candidate vaccine for TB. It effectively induces comprehensive and persistent immune protection, particularly at the mucosal site, offering a novel and strategic direction for preventing TB in adults.
Zitieren
APA
Wu, Y., Ma, W., Duan, H., Fu, X., Wang, J., Yang, C., Gu, Q., Jia, Y., Zhang, Y., Ma, F., Wei, Z., Ren, B., Wang, Q., Hei, Y., Ma, Q., & Li, B. (2026). Inhalable bionic nanoparticle vaccine mimicking pulmonary surfactant enhances anti-tuberculosis immunity. European Cells & Materials, 57. https://doi.org/10.22203/ecm.v057a03
Vancouver
Wu Y, Ma W, Duan H, Fu X, Wang J, Yang C, et al. Inhalable bionic nanoparticle vaccine mimicking pulmonary surfactant enhances anti-tuberculosis immunity. European Cells & Materials. 2026;57. doi:10.22203/ecm.v057a03
BibTeX
@article{Wu2026,
author = {Wu, Yanqiu and Ma, Weifeng and Duan, Han and Fu, Xinting and Wang, Jiamei and Yang, Chunhua and Gu, Qin and Jia, Yue and Zhang, Yunlong and Ma, Fei and Wei, Zihui and Ren, Bohua and Wang, Qinqin and Hei, Yuehua and Ma, Qiang and Li, Bin},
title = {Inhalable bionic nanoparticle vaccine mimicking pulmonary surfactant enhances anti-tuberculosis immunity},
journal = {European Cells & Materials},
year = {2026},
volume = {57},
doi = {10.22203/ecm.v057a03}
}
EUVIMED